- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.09. | A wild ride for TransThera investors: what's the story? | 1 | Bamboo Works | ||
| 19.09. | TRANSTHERA-B (02617): INTERIM REPORT 2025 | 2 | HKEx | ||
| TRANSTHERA SCIENCES Aktie jetzt für 0€ handeln | |||||
| 17.09. | HSI Extends Gains to 400+ Pts; JD-SW/MEITUAN-W/BABA-W Soar 4-5%; SMIC Reaches New High; TRANSTHERA-B Rebounds ~20% | 8 | AASTOCKS | ||
| 17.09. | TRANSTHERA-B Rebounds 20%+; No Comments Given on Wild Ride in Stock Price | 1 | AASTOCKS | ||
| 16.09. | TRANSTHERA-B Reverts Down 20% after Midday | 2 | AASTOCKS | ||
| 16.09. | TRANSTHERA-B Says Unaware of Reasons for Unusual Shr Price & Volume Changes | 1 | AASTOCKS | ||
| 16.09. | HSI Closes Midday at 26,466, Up 19 pts; HSTI Closes Midday at 6,067, Up 23 pts; CHINAHONGQIAO Down over 5%; NTES, HSBC HOLDINGS, BAYZED HEALTH, TRANSTHERA-B, BRAINAURORA-B Hit New Highs | 9 | AASTOCKS | ||
| 16.09. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS | 1 | HKEx | ||
| 16.09. | HSI Once Tops 26,600-mark to Hit 4-Yr High; Newcomers in Stock Connect Surge; BAYZED HEALTH, TRANSTHERA-B Soar 47-54% | 1 | AASTOCKS | ||
| 16.09. | TRANSTHERA-B Once Leaps 64% in Early Trading, Soaring 50x in Less Than 3 Mths Since Debut, Surpassing HANSOH PHARMA in Mkt Cap | 6 | AASTOCKS | ||
| 16.09. | TRANSTHERA-B Opens Up 15% to Hit New Highs, Surpassing SINO BIOPHARM, CSPC PHARMA in Mkt Cap w/35x Surge in Less Than 3 Mths Since Debut | 19 | AASTOCKS | ||
| 15.09. | HSI Closes at 26,446, Up 58 pts; HSTI Closes at 6,043, Up 54 pts; WUXI BIO Up over 6%; BABA, NONGFU SPRING, NTES, TRANSTHERA-B, BAYZED HEALTH Hit New Highs; Market Turnover Rises | 12 | AASTOCKS | ||
| 15.09. | HSI Closes Midday at 26,463, Up 75 pts; HSTI Closes Midday at 6,055, Up 66 pts; POP MART Down over 7%; BABA, NTES, BAYZED HEALTH, BRAINAURORA-B, TRANSTHERA-B Hit New Highs | 14 | AASTOCKS | ||
| 10.09. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT PHASE II IND APPROVAL OF TINENGOTINIB IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF PREVIOUSLY TREATED ... | - | HKEx | ||
| 04.09. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED IN PHASE II CLINICAL TRIAL OF TINENGOTINIB IN COMBINATION WITH AKESO'S (CADONILIMAB, ... | - | HKEx | ||
| 25.08. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT INCLUSION OF THE COMPANY AS A CONSTITUENT OF THE HANG SENG INDEX SERIES | 1 | HKEx | ||
| 25.08. | TRANSTHERA-B (02617): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2025 | 1 | HKEx | ||
| 25.08. | TRANSTHERA-B (02617): CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG | - | HKEx | ||
| 13.08. | TRANSTHERA-B (02617): DATE OF BOARD MEETING | - | HKEx | ||
| 04.08. | TRANSTHERA-B (02617): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 4 AUGUST 2025 | - | HKEx |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ARCUTIS BIOTHERAPEUTICS | 20,050 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 | ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere... ► Artikel lesen | |
| 89BIO | 14,800 | 0,00 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,305 | 0,00 % | RECURSION PHARMACEUTICALS INC zündet den Turbo jetzt! | ||
| BEAM THERAPEUTICS | 26,340 | 0,00 % | Jefferies stuft Beam Therapeutics auf "Buy": Kommende Katalysatoren im Fokus | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 10,290 | 0,00 % | Oppenheimer senkt Kursziel für Moonlake Immunotherapeutics nach durchwachsenen Studienergebnissen | ||
| LENZ THERAPEUTICS | 38,740 | 0,00 % | Piper Sandler raises LENZ Therapeutics stock price target to $67 on VIZZ launch | ||
| MINERALYS THERAPEUTICS | 42,170 | +7,06 % | Mineralys Therapeutics: Aktie erreicht Rekordhoch von 41,11 USD | ||
| ARCELLX | 86,80 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 52,45 | 0,00 % | Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million |
SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for... ► Artikel lesen | |
| BIONTECH | 89,30 | +1,65 % | BioNTech Aktie zeigt Stärke: Es wird spannend! | Seit dem letzten 4investors.de-Chartcheck zur BioNTech Aktie hat sich einiges getan. Der Aktienkurs des Mainzer Biotech-Konzerns ist an der NASDAQ um rund 9 Dollar gestiegen, hat die 20- und 50-Tage-Linie... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 49,740 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,320 | -5,87 % | UBS bestätigt Kaufempfehlung für Summit Therapeutics vor ESMO-Daten | ||
| COGENT BIOSCIENCES | 16,250 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WALTHAM, Mass. and BOULDER, Colo., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| BICARA THERAPEUTICS | 17,780 | 0,00 % | Bicara Therapeutics Inc.: Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Updated data from Phase 1/1b trial presented at 2025 ASCO Annual Meeting demonstrated deep and durable responses in 1L HPV-negative R/M HNSCC Data from additional Phase 1/1b expansion cohorts evaluating... ► Artikel lesen | |
| LEXEO THERAPEUTICS | 8,240 | 0,00 % | Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy | U.S. Food and Drug Administration (FDA) open to pooling data from ongoing Phase I/II studies of LX2006 with pivotal data to support a Biologics License Application (BLA) for Accelerated Approval Interim... ► Artikel lesen |
TRANSTHERA SCIENCES NANJING INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRANSTHERA SCIENCES NANJING INC finden Sie auf Wallstreet Online.